A large number of companies from various sectors, ranging from biotechnology to real estate investment firms, have initiated IPO roadshows on Monday as issuers gear up to move forward with their IPO plans amidst the Middle East conflict.
Analysts believe that conditions are favorable for a gradual recovery of activity in the coming months, provided that the volatility subsides.
The owner of convenience store chain Yesway, the proteomics company Alamar Biosciences, obesity drug developer Kailera Therapeutics, and real estate investment company National Healthcare Properties unveiled the terms of their respective offerings on Monday.
“This reflects the number of companies waiting on the sidelines for an IPO, just waiting for a sign of stability. A number of issuers just need to see a sign of stability, and they will launch their offerings,” said Matt Kennedy, principal strategist at Renaissance Capital, a research provider and ETF focused on IPOs.
The VIX volatility index, Wall Street’s fear gauge, dropped below 20 last week for the first time in over a month.
A value below 20 may indicate greater stability in the markets.
HOPE FOR A REBOUND IN IPOs REMAINS INTACT
The IPO market struggled to gain momentum in February and March, as market volatility related to AI disruption fears and the Middle East conflict sidelined issuers.
However, “2026 is still on track to be the best year for IPOs since the post-pandemic drought, and it could even achieve that without mega-listings,” said Lukas Muehlbauer, an IPOX research associate.
“Pricing discipline and attractive valuations make this year a buyer’s market, giving these deals a better chance of trading well post-IPO.”
From defense to REIT sectors, six companies filed for IPOs last Friday, bolstering the short-term pipeline.
However, some uncertainty remains after weekend talks between the United States and Iran failed to reach an agreement to end the war.
Bill Ackman’s Pershing Square also kicked off a roadshow for IPOs in the United States from the billionaire investor’s management company and a new fund.
